moxifloxacin intravenous / Generic mfg. - LARVOL DELTA

Amide-functionalized cellulose derived from sugarcane bagasse for efficient removal of amoxicillin and moxifloxacin from water. (PubMed, Int J Biol Macromol) - "The maximum adsorption capacities (qmax) obtained under optimized experimental condition were 473.46 mg/g and 435.38 mg/g for AMX and MOX respectively. Owing to low cost and high efficiency, amide functionalized cellulose obtained from sugarcane bagasse could be used as an alternative adsorbent to expensive commercial adsorbents for the removal of antibiotics and other pollutants from water."

Journal

Clinical evaluation of a commercial culture-free targeted next-generation sequencing test for diagnosis of drug-resistant tuberculosis. (PubMed, Microbiol Spectr) - P=N/A | "The ABL tNGS workflow showed ≥95% sensitivity for rifampicin, isoniazid, and levofloxacin; 92%-93% for pyrazinamide and moxifloxacin; 88% for ethambutol; and 72%-82% for bedaquiline and clofazimine. Further refinement in sample preparation may expand its use to specimens with lower bacterial counts. This study is registered with ClinicalTrials.gov as NCT04239326."

Journal • Next-generation sequencing • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Overcoming Antimicrobial Resistance in Bacterial Keratitis With an Antibiotic-Eluting Contact Lens. (PubMed, Invest Ophthalmol Vis Sci) - "This study evaluated a therapeutic contact lens (M-TCL) designed to provide sustained, localized high drug concentrations of moxifloxacin-a commonly used broad-spectrum antibiotic-as a potential treatment for drug-resistant BK...M-TCLs were safe in rabbits. M-TCLs offer a promising therapy for BK and may serve as a potential therapy for drug-resistant BK."

Journal • Infectious Disease • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

In silico assessment of neuromuscular blocking agents and fluoroquinolones as ligands of the Mas-related G protein-coupled receptor X2. (PubMed, Pharmacol Rep) - "In contrast to fluoroquinolones, NMBAs displayed different affinity for MRGPRX2. Cellular responses in bench experiments closely reflected the MD predictions. Alanine scanning revealed that the MRGPRX2 binding pocket exhibits low susceptibility to single-site mutations that enhance receptor responsiveness."

Journal • Immunology

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia (ASH 2025) - "Real-world data on infection incidence,microbiology, prophylaxis, and risk factors remain limited.We retrospectively analyzed 60 RRMM patients treated with compassionate access single-agent anti-BCMA bispecifics (teclistamab 95%, elranatamab 5%) in British Columbia (May 2023-June 2025), as perstandard indications...Pneumocystis prophylaxis withtrimethoprim/sulfamethoxazole was used in 95% of patients, prophylactic anti-microbial in the first 3months in 80% (doxycycline 54%, levofloxacin 44%, moxifloxacin 2%); valacyclovir in 100%; G-CSF in 48%.In total, 58% received intravenous immunoglobulin (IVIG), 35% of which initiated prior to first infection,either prior to bispecific (15%) or as primary prophylaxis (20%)...Infections were frequent in RRMM patients receiving anti-BCMA bispecific therapy, particularlyrespiratory infections. Early prophylactic antimicrobials may reduce bacterial infections but rates remainhigh beyond 100 days when these are stopped. Early..."

Clinical • Cardiovascular • Cytomegalovirus Infection • Dermatology • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Multiple Myeloma • Nephrology • Neutropenia • Otorhinolaryngology • Pneumonia • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Septic Shock • Sinusitis • Varicella Zoster

Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study. (PubMed, Front Drug Discov (Lausanne)) - "We conclude that cobicistat can attenuate moxifloxacin induced FPDcF prolongation at clinically relevant concentrations in vitro. Taken together, this work provides a foundation to evaluate drug combinations in vitro to aid regulatory decision-making and reduce the dependence on animal studies."

Journal • Cardiovascular

P030 From nerve to nodules: the unexpected progression of pure neuritic leprosy to lepromatous leprosy with erythema nodosum leprosum. (PubMed, Br J Dermatol) - "The patient was started on World Health Organization-recommended multidrug therapy with rifampicin, dapsone and clofazimine for 12 months...The patient was started on a regimen of monthly pulsed rifampicin, minocycline and moxifloxacin for 12 months. Thalidomide was started to manage the severe ENL reaction...Only one such case has been previously reported. This emphasizes the need for early diagnosis, vigilant follow-up and awareness of potential disease transformations, particularly in endemic areas."

Journal • Dermatology • Immune Modulation • Immunology • Infectious Disease • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

QUANTUM: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (clinicaltrials.gov) - P3 | N=532 | Recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

The prevalence and molecular epidemiology of Clostridioides difficile in hospital-based pediatric populations in China. (PubMed, Emerg Microbes Infect) - "High resistance to clindamycin (64.5%) was observed, primarily mediated by ermB, while all isolates remained susceptible to metronidazole and vancomycin. Moxifloxacin resistance (10.7%) was associated with gyrA T82I mutations, particularly in toxigenic ST3 strains...Genomic relatedness (≤2 SNPs) was detected in 12.0% of asymptomatic carriers, with most links associated with hospital-wide contact, suggesting possible transmission events. This study highlights the importance of asymptomatic colonized children as a reservoir for C. difficile, maintaining resistant lineages and disseminating AMR, thereby underscoring the need for enhanced surveillance and targeted antimicrobial stewardship in Chinese healthcare settings."

Journal • Infectious Disease • Pediatrics

Clinical characteristics, antimicrobial susceptibility patterns, and treatment outcomes of nontuberculous mycobacterial diseases in eastern China: a retrospective cohort study (2019-2022). (PubMed, Microbiol Spectr) - "Antimicrobial susceptibility testing revealed that Mycobacterium avium complex exhibited relatively favorable sensitivity to clarithromycin, amikacin, ethambutol, rifapentine, rifampicin, and moxifloxacin, while the Mycobacterium chelonae/Mycobacterium abscessus complex showed sensitivity only to amikacin (66.7%). By linking pathogen types, drug resistance, and treatment duration to outcomes, this work equips doctors in Eastern China to diagnose faster, choose effective therapies, and improve patient survival. These findings also urge policymakers to prioritize localized data collection and standardized protocols for NTM management globally."

Journal • Retrospective data • Bronchiectasis • Chronic Cough • Cough • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Whole-Genome and Targeted Sequencing of 75 Drug-Resistant Mycobacterium tuberculosis Clinical Isolates in South Korea. (PubMed, Ann Lab Med) - "Specifically, we analyzed mutations associated with resistance against isoniazid (INH), rifampicin (RIF), moxifloxacin (MFX), pyrazinamide (PZA), pretomanid (PMD), delamanid (DLM), linezolid (LZD), and bedaquiline (BDQ) and compared them with those in the 2023 WHO mutation catalog. However, PZA results were discrepant for 16 isolates. Our findings highlight the potential of WGS and targeted sequencing as powerful tools for diagnosing TB drug resistance and emphasize the need for further validation before their routine implementation in clinical settings."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Characterization of Methicillin-Resistant Staphylococcus Aureus Resistance and Hematological Profiles in Diabetic Foot Infections. (PubMed, Clin Lab) - "This study examined the characteristics of DFU-associated MRSA infection, particularly its multidrug resistance features. MRSA infection demonstrated 100% sensitivity to vancomycin and linezolid. The findings suggest that combined detection of MCHC, D-dimer, ALB, ALP, Na+, Cl-, and Ca2+ may serve as a valuable reference for the early identification of DFU-associated MRSA infection in clinical settings. Clinicians should be mindful of MRSA infection risks in patients with DFU and develop individualized anti-infection regimens based on drug sensitivity profiles to improve prognosis."

Journal • Retrospective data • Hematological Disorders • Infectious Disease

Adapting global guidelines to local contexts: optimising community-acquired pneumonia (CAP) specific prescribing in Pakistan to counter antimicrobial resistance. (PubMed, BMJ Open Respir Res) - "Most physicians were unaware of the exact prevalence of causative pathogens and their resistance patterns in Pakistan due to the unavailability of robust local data. Consequently, international guidelines were adapted to local challenges including resistance patterns, limited diagnostics and resource constraints. Physicians prioritised beta-lactam antibiotics use and restricted moxifloxacin and azithromycin to mitigate resistance propagation linked to multidrug-resistant tuberculosis and extensively drug-resistant typhoid. Efforts to improve antimicrobial utilisation for CAP in Pakistan need to address implementation barriers and focus on enhancing diagnostic access, vaccine coverage and funding for treatment optimisation."

Journal • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol. (PubMed, BMJ Open Respir Res) - P2 | "EUDRACT number: 2021-001626-22. CTIS: 2023-509075-17-00."

Clinical protocol • Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Novel cyclic heptapeptides as potential therapeutics against methicillin-resistant Staphylococcus aureus infections. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Antibacterial evaluation against MRSA, methicillin-sensitive Staphylococcus aureus (MSSA), and vancomycin-resistant Staphylococcus aureus (VRSA) revealed that cyclic heptapeptide Ala6 shown the strongest activity (minimum inhibitory concentration (MIC), 22.1-39.5 µg/mL), comparable to moxifloxacin, followed by cyclic heptapeptide Gly6 (moderate activity) and Tyr6 (least activity). Hemolysis testing confirmed cyclic heptapeptide Ala6's excellent biocompatibility ( 9.3% at 10 µg/mL), while moxifloxacin caused minimal hemolysis. The best peptide was further investigated through molecular dynamics (MD) simulations and density functional theory (DFT) studies."

Journal • Hematological Disorders • Infectious Disease

Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database. (PubMed, Front Pharmacol) - "HREL could be an option for younger patients (<60 years), though vigilance for hepatotoxicity and IRIS-TB is needed, especially in females. For males on HREM, increased attention to neurological AEs is recommended."

Adverse events • Journal • Eosinophilia • Hepatology • Infectious Disease • Liver Failure • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. (PubMed, EClinicalMedicine) - P3 | "75A50120C00001. The contract and federal funding are not an endorsement of the study results, products, or company."

Head-to-Head • Journal • P3 data • CNS Disorders • Infectious Disease • Insomnia • Pain • Pneumonia • Respiratory Diseases • Sleep Disorder

Coxiella burnetii Should Not Be Ignored: Two Cases of Q Fever Pneumonia Diagnosed by Metagenomic Next-Generation Sequencing. (PubMed, Infect Drug Resist) - "Ultimately, two patients were diagnosed with Q fever pneumonia, and the symptoms of patients were significantly improved after timely treatment with the special drug doxycycline and moxifloxacin, and lung inflammation in both patients were effectively absorbed in the subsequent follow-up examination. As a zoonotic pathogen, C. burnetii should not be ignored. The One Health approach may be suitable for Q fever prevention and control."

Biomarker • Journal • Next-generation sequencing • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases

Antimicrobial resistance patterns of Nocardia species in clinical isolates from Argentina (2020-2022). (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - "This first Argentine nationwide surveillance study confirms trimethoprim-sulfamethoxazole and linezolid as reliable empiric therapy options while highlighting concerning resistance to fluoroquinolones and macrolides. The observed methodological discordance emphasizes the critical need for standardized antimicrobial susceptibility testing protocols for Nocardia species."

Journal • Infectious Disease

Clinical impact of antibiotic resistance in odontogenic infections: a 12-year analysis of 740 cases. (PubMed, Clin Oral Investig) - "Continuous resistance surveillance and adaptation of empirical therapy are essential for managing severe odontogenic infections and reducing life-threatening infection-related complications, emphasizing the need for antimicrobial stewardship."

Journal • Retrospective data • Immunology • Infectious Disease

Tailored management of chronic bacterial prostatitis with sequential fluoroquinolones and adverse effect mitigation strategies: A case report. (PubMed, IDCases) - "Management involved sequential fluoroquinolone therapy-ciprofloxacin followed by moxifloxacin-over 6.5 weeks, guided by clinical condition and pharmacokinetic/ pharmacodynamic (PK/PD) considerations. Follow-up focused on prostate-specific antigen (PSA) monitoring, symptom tracking, and referral to pelvic floor physical therapy. This case's approach combining sequential fluoroquinolone therapy with structured ADR-prevention strategies and a patient-engaged, shared decision-making model underscores the importance of individualized, multidisciplinary care in CBP."

Adverse events • Journal • Allergy • Immunology • Infectious Disease • Pain

Psittacosis chlamydia pneumonia complicated with organizing pneumonia: a case report and literature review. (PubMed, Front Med (Lausanne)) - "Although the lesions partially resolved after moxifloxacin therapy, the patient experienced recurrent episodes...During treatment of C. psittaci pneumonia, if empirical anti-infective therapy shows no response after three days, or if imaging reveals features such as consolidation, migratory lesions, or a reverse halo sign, the possibility of concurrent OP should be considered. Pathological examination is recommended in such cases to avoid missed diagnosis and to ensure timely intervention."

Journal • Cough • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

An expanding abdominal aorta ulcer as a rare complication of Staphylococcus aureus sepsis in a hemodialysis patient: A case report. (PubMed, Medicine (Baltimore)) - "Aortic infections in dialysis patients are therapeutically challenging. Serial biomarker monitoring and imaging are crucial for detecting disease progression, even with improved clinical symptoms."

Journal • Anorexia • Cardiovascular • Chronic Kidney Disease • Infectious Disease • Inflammation • Nephrology • Pain • Renal Disease • Septic Shock • CRP

A PAN-USR TB Multi-Center Trial (clinicaltrials.gov) - P3 | N=610 | Recruiting | Sponsor: Shenzhen Third People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Engineered Cu3P-ZnWO4 heterojunction integrated with porous polymer monolithic template for enhanced photocatalytic degradation of organic pollutants. (PubMed, Sci Rep) - "Based on VB-XPS analysis and trapping experiments, a feasible photocatalytic mechanism was proposed to clarify the reactive species predominantly participating in the photocatalytic process. This work demonstrates an efficient and sustainable approach for removing moxifloxacin drug residues, underscoring the potential of nanocomposite-encapsulated polymer monoliths as a next-generation photocatalytic platform for future water treatment applications."

Journal